Sphera Funds Management LTD. raised its stake in Apellis Pharmaceuticals Inc (NASDAQ:APLS) by 91.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 212,470 shares of the company’s stock after buying an additional 101,667 shares during the quarter. Sphera Funds Management LTD.’s holdings in Apellis Pharmaceuticals were worth $3,778,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently bought and sold shares of APLS. venBio Partners L.P. acquired a new position in Apellis Pharmaceuticals in the second quarter valued at about $72,482,000. Hillhouse Capital Management Ltd. lifted its position in Apellis Pharmaceuticals by 203.0% in the second quarter. Hillhouse Capital Management Ltd. now owns 4,328,289 shares of the company’s stock valued at $95,222,000 after buying an additional 2,899,718 shares during the last quarter. BlackRock Inc. lifted its position in Apellis Pharmaceuticals by 152.9% in the second quarter. BlackRock Inc. now owns 2,798,968 shares of the company’s stock valued at $61,578,000 after buying an additional 1,692,121 shares during the last quarter. Millennium Management LLC acquired a new position in Apellis Pharmaceuticals in the second quarter valued at about $19,656,000. Finally, Victory Capital Management Inc. increased its stake in Apellis Pharmaceuticals by 150.2% during the second quarter. Victory Capital Management Inc. now owns 932,753 shares of the company’s stock worth $20,520,000 after purchasing an additional 559,913 shares during the period. 55.94% of the stock is currently owned by institutional investors.
Shares of NASDAQ:APLS opened at $17.73 on Friday. The company has a quick ratio of 14.91, a current ratio of 14.90 and a debt-to-equity ratio of 0.14. Apellis Pharmaceuticals Inc has a 1 year low of $11.45 and a 1 year high of $32.00.
Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings results on Tuesday, November 13th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.69) by $0.05. Equities research analysts forecast that Apellis Pharmaceuticals Inc will post -2.38 earnings per share for the current year.
In other news, major shareholder Morningside Venture Investment bought 81,323 shares of the business’s stock in a transaction that occurred on Friday, September 21st. The shares were purchased at an average cost of $19.48 per share, for a total transaction of $1,584,172.04. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel David O. Watson sold 15,776 shares of the company’s stock in a transaction that occurred on Friday, September 14th. The stock was sold at an average price of $18.78, for a total transaction of $296,273.28. The disclosure for this sale can be found here. 9.30% of the stock is owned by corporate insiders.
A number of analysts have issued reports on APLS shares. Cantor Fitzgerald set a $53.00 price target on shares of Apellis Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, December 3rd. Citigroup boosted their price target on shares of Apellis Pharmaceuticals from $34.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday. Zacks Investment Research lowered shares of Apellis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, November 16th. ValuEngine upgraded shares of Apellis Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Finally, JPMorgan Chase & Co. cut their price target on shares of Apellis Pharmaceuticals from $38.00 to $34.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 14th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $38.67.
ILLEGAL ACTIVITY WARNING: “Apellis Pharmaceuticals Inc (APLS) Holdings Lifted by Sphera Funds Management LTD.” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/12/08/apellis-pharmaceuticals-inc-apls-holdings-lifted-by-sphera-funds-management-ltd.html.
Apellis Pharmaceuticals Profile
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology.
Featured Story: What type of investment options does a Roth IRA provide?
Want to see what other hedge funds are holding APLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apellis Pharmaceuticals Inc (NASDAQ:APLS).
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.